154results about How to "Lower systolic blood pressure" patented technology

A method and device for delivering and monitoring baroreflex and drug therapy to manage hypertension. The method includes providing an implanted an implanted medical device configured to automatically detect drug-related effects on the autonomic nervous system including the steps of measuring a physiologic status of the autonomic nervous system at desired intervals, logging the physiologic status of the autonomic nervous system at desired intervals, monitoring the measured and logged physiologic status of the autonomic nervous system for any changes and correlating the changes to a corresponding drug administration time. The device includes an implanted baroreflex activation device capable of administering one or more hypertension treatment drugs including a controller that activates and adjusts therapy delivery, a baroreflex activation therapy delivery device, a drug therapy delivery device and a device that senses physiologic parameters.

An implantable blood pressure regulator is provided. The blood pressure regulator includes at least one connection zone and an attenuation zone. The connection zone is suitable for connection to a body conduit, such as a blood vessel. The attenuation zone is movable from a first state to a second state in response to a physiological pressure spikes. The movement from the first state to the second state lowers a level of pressure or dampens a pressure spike in the body conduit.

An implantable blood pressure regulator is provided. The blood pressure regulator includes at least one connection zone and an attenuation zone. The connection zone is suitable for connection to a body conduit, such as a blood vessel. The attenuation zone is movable from a first state to a second state in response to a physiological pressure spikes. The movement from the first state to the second state lowers a level of pressure or dampens a pressure spike in the body conduit.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B orα2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

The invention belongs to the technical field of natural product preparation and particularly relates to a method for preparing high-activity corn antihypertensive peptide and a special device. An enzyme membrane reactor comprises a reaction tank, a temperature control system, an automatic pH dripping instrument, a strong force stirrer, a material liquid storage tank, a peristaltic pump, a control valve, a pressure meter, an ultrafiltration membrane assembly, a pipeline heat exchanger, a collection tank, a liquid level controller, a nanofiltration membrane assembly and the like. The process method comprises the following steps that corn gluten meal is subjected to alcohol alkali liquid extraction to obtain concentrated corn protein, the concentrated corn protein is pretreated at high temperature and is then added into a continuous enzyme membrane reactor system, the corn antihypertensive peptide is prepared by adopting the enzyme membrane coupling technology, then, the products are subjected to ultrafiltration grading through the ultrafiltration membrane assembly and then are subjected to desalting through the nanofiltration membrane, and the high-activity corn antihypertensive peptide is obtained. The inhibitory activity of the obtained corn antihypertensive peptide on angiotensin-converting enzyme (ACE) is maintained at a value higher than 86 percent, the protein recovery rate reaches higher than 70 percent, and in addition, the systolic pressure of spontaneously hypertensive rats can be obviously reduced.

The invention discloses functional nutritional blend oil and a preparation method thereof, and belongs to the field of healthy blend oil. The functional nutritional blend oil is formed by blending the following components in percentage by weight: 50 to 92 percent of rice oil serving as a main raw material, 8 to 50 percent of one or more other edible vegetable oils, 0.5 to 1.2 percent of octacosanol, and 0.6 to 1 percent of resveratrol. The other edible vegetable oils are one or more of safflower seed oil, corn oil, soybean oil, olive oil, linseed oil, sunflower seed oil and peanut oil. The invention solves the problems that the conventional edible oil is single in nutrient and unbalanced in content and lacks functional components, and provides the edible vegetable blend oil which is in accordance with an optimal proportion of multiple unsaturated fatty acids such as omega-6 (linoleic acid) and omega-3 (linolenic acid) recommended by Chinese Society of Nutrition and is functional and stable.

The invention discloses a brand-new oral solid medicinal composition. The medicinal composition is an oral preparation prepared from hydrochlorothiazide, levamlodipine, valsartan and pharmaceutically acceptable auxiliaries, and the oral preparation comprises but is not limited to tablets or capsules. The composition comprises the following raw materials in parts by weight: 5-25 parts of the hydrochlorothiazide, 2.5-5 parts of the levamlodipine, 80-160 parts of the valsartan, 40-120 parts of microcrystalline cellulose, 30-90 parts of compressible starch, 5-25 parts of cross-linked sodium carboxymethylcellulose, 3-8 parts of silicon dioxide and 1-2 parts of stearic acid. The medicinal composition disclosed by the invention has the advantages of scientific and reasonable prescription, low auxiliary content and high bioavailability, and is a first choice of medicine for treating hypertension.

Dietary supplements useful for treating or preventing cardiac disease are disclosed According to some embodiments, the presently disclosed supplement includes a pomegranate product fermented with a statin-producing fungus such one or more of Monascus, Aspergillus, Penicillium, Pleurotus, Pythium, Hypomyces, Paelicilomyces, Eupenicillium, and Doratomyces. Alternatively or additionally, the presently disclosed supplement includes a pomegranate product in combination with a plant product, such as a grain product and a legume, fermented with the statin-producing fungus. Optionally, the supplement includes at least one of coenzymeQ10 and a tocopherol. The presently disclosed dietary supplements include both a COX-2 inhibitor and a HMG-CoA reductase inhibitor, and in some embodiments, the supplement is useful for reducing or controlling blood cholesterol for managing atherosclerotic disease, and / or for managing blood pressure. Methods of preparing the presently disclosed dietary supplement are also provided.

The invention discloses nutrient food for a sub healthy group. The nutrient food comprises oat flour, isolated soybean protein, flaxseeds, broccoli, cherry tomatoes, okras, coconuts, pawpaw, mangoes, noni fruits, oat dietary fibers, fructose-oligosaccharide, spiral seaweeds, vine tea, green tea, plant comprehensive ferment, L-carnitine, taurine, octacosanol, vitamin B1, vitamin B2 and nicotinic acid. The nutrient food can solve the problem that an existing sub health conditioning health product is single in nutrient component and fuzzy in suitable people; total-nutrient vegetable food which is convenient to eat and good in mouthfeel is specially designed according to the factors of daily routine, a body condition and the like of the sub health conditioning health product suitable people, so that required nutrients of the suitable people can be quickly compensated in a balanced manner. The nutrient food is beneficial to guaranteeing the special nutrient needs of the people, so that the quality and the acceptability of the product are guaranteed, and the health condition of the target people is finally improved.

The invention provides a camellia nitidissima milk tea with the health care functions of blood pressure lowering, blood lipid lowering and blood sugar lowering. According to the technical scheme of the invention, the formula of the milk tea comprises, by weight: 20-40 parts of camellia nitidissima, 5-15 parts of tea leaves, 20-50 parts of skim milk powder, 5-15 parts of xylitol, 0.05-0.5 parts of potassium sorbate, and 200-400 parts of water. With fresh, sweet and mellow tastes, the camellia nitidissima milk tea of the invention has the health care functions of lowering blood pressure, blood lipid and blood sugar, and is suitable for patients with high blood pressure, high blood lipid and high blood sugar as well as for auxiliary health care of vast customers in daily food.

The invention relates to a benzothiazole derivative, a preparation method and an application thereof, wherein the benzothiazole derivative is 2-m-aniline benzothiazole-1H-pyrazole-3-formamide, and the structural formula of the benzothiazole derivative is shown in the description. The benzothiazole derivative disclosed by the invention can accelerate the growth of saccharomycetes, strengthen the metabolic activity of the saccharomycetes, obviously reduce the plasma triglyceride, the total cholesterol and the high-density lipoprotein of C57 BL / 6J mice fed with high-fat feedstuff, reduce the systolic pressure and the diastolic pressure of model mice, reduce the fasting blood glucose of the model mice, improve the sugar tolerance of the mice, affect the expression of SIRT1 and relevant genes (FOXO1, P53, PPAB gamma and PGC-1 alpha), and obviously improve the sugar and fat metabolism of diabetic model mice. Therefore, the benzothiazole derivative can be applied to preparing medicines for preventing and treating diabetes mellitus and complications of the diabetes mellitus.

Compounds are provided that lower blood glucose concentrations, lower serum triglyceride concentrations, lower systolic blood pressure, and increase glucose uptake by adipose tissue, but do not affect the expression of PPAR-γ by adipose tissue.

The invention discloses a novel oral solid medicinal composition. The novel oral solid medicinal composition is an oral preparation prepared from hydrochlorothiazide, levamlodipine besylate, candesartan cilexetil and pharmaceutically acceptable auxiliary materials. The novel oral solid medicinal composition can be processed into tablets, capsules and the like. Specifically, the novel oral solid medicinal composition comprises: be weight, 5 to 25 parts of hydrochlorothiazide, 2.5 to 5 parts of levamlodipine besylate, 4 to 20 parts of candesartan cilexetil, 30 to 60 parts of microcrystalline cellulose, 30 to 60 parts of compressible starch, 30 to 50 parts of crosslinked polyvinylpyrrolidone, 1 to 2 parts of silica and 0.5 to 2 parts of magnesium stearate. The novel oral solid medicinal composition has a scientific and reasonable formula, low auxiliary material content and high bioavailability. Therefore, the novel oral solid medicinal composition is a drug of first choice for the treatment of hypertension.

An anti-diabetic or anti-hypertensive fish protein hydrolysate is provided, in which the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein is hydrolysed by a metalloendopeptidase obtainable from Bacillus amyloliquefaciens. Methods of making and methods for using such fish protein hydrolysates are also provided.

The invention discloses a health care product for cleaning colon and promoting defecation, and eliminating toxin and beautifying skin and a preparation method of same. The health care product is mainly prepared from the following raw materials by the following steps: smashing cleaned and baked inflatedfruit senna seed, baked flower, and baked inflatedfruit senna stem leaf by an ultra-micro pulverizer into 360 to 450 meshes, then airing and sterilizing the obtained product to obtain inflatedfruit senna powder; and filling the inflatedfruit senna powder into capsules to prepare hard and soft capsules for eliminating toxin and beautifying skin. The Chinese herbal medicaments are organically combined, perform treatment based on the syndrome differentiation, are mutually supported, and have the effects of eliminating toxin and beautifying skin, lubricating bowel and promoting defecation, eliminating halitosis and clearing toxicants accumulated at gastrointestinal tracts, so as to achieve the purposes of cleaning colon and promoting defecation, and treating constipation. More importantly, the health care product is very gentle and can solve constipation without causing diarrhea. Meanwhile, the product is selected from natural raw materials which are free from pesticide residue pollution, and has no preservatives to achieve the effects of clearing heat and refreshing, cooling down and cleaning colon, repressing the liver and improving eyesight, resisting cancer and aging, and strengthening the immunity for a patient; and furthermore, the product has no toxin or side effect after being taken for a long time and improves the body immunity.

The invention discloses a Fumailing capsule for preventing and treating slow arrhythmia and a preparation method of the Fumailing capsule. The capsule is prepared from the following traditional Chinese medicinal materials: 8-12g of ephedra, 8-10g of aconite roots, 2-4g of asarum herb, 25-32g of prepared liquorice roots, 10-14g of radix ginseng, 10-12g of ramulus cinnamomi, 25-32g of prepared rhizome of rehmannia, 8-10g of bretschneider pear pericarp, 10-12g of carthamus tinctorius, 8-10g of fragrant solomonseal rhizome, 10-12g of fossil fragment, 10-14g of curcuma roots, 18-22g of astragalus mongholicus, 26-32g of salvia miltiorrhiza, 8-10g of ginger and 26-30g of Chinese dates. Fumailing particles prepared from the traditional Chinese medicinal materials such as the ephedra, the aconite roots and the asarum herb are used for preventing and treating the slow arrhythmia; the materials are easy to obtain; the preparation method is simple; and the Fumailing capsule has a significant treatment effect on the arrhythmia, takes effect quickly, is safe to use and has no toxic or side effects, and can improve a sinoatrial node function and prevent and treat sinoatrial node hypofunction caused by various reasons.

The invention discloses an effective portion extracted from a conical hydrangea (Hydrangea paniculata sieb), and the preparation method of the effective portion comprises drug composite of the effective portion and the purpose of the effective portion and other drug composite which are used as drugs, and the effective portion is particularly applied in preparing drugs for preventing and / or treating kidney incompetence, high blood pressure and diabetic kidney disease.

The invention discloses a gynura divaricata (L.) DC jelly, and provides a jelly with health functions of reducing blood pressure, blood fat and blood sugar and the like. The gynura divaricata (L.) DC jelly comprises the following components in percentage by weight: 10 to 30 percent of gynura divaricata (L.) DC extract, 8 to 20 percent of xylitol, 0.5 to 0.7 percent of agar, 0.15 percent of citric acid and the balance water, wherein the gynura divaricata (L.) DC extract is prepared from gynura divaricata (L.) DC by a Chinese medicine decocting method. The gynura divaricata (L.) DC jelly has effects of clearing heat and releasing toxin, has the health functions of reducing blood pressure, blood fat and blood sugar and the like, and is suitable for auxiliary health care of daily foods for patients suffering from high blood pressure, high blood fat, high blood sugar and the like.

The invention provides kelp micro powder lotus seed paste with health care function of lowering blood pressure, blood lipid and blood sugar. The lotus seed paste comprises the following components by weight percent: 40-70% of lotus seed micro powder, 10-15% of xylitol, 10-20% of vegetable oil, 10-20% of kelp micro powder, 0.5-2% of ginger juice and 0.5-2% of edible alcohol, wherein the lotus seedmicro powder and the kelp micro powder are made by an ultra-micro pulverizer and have grain size of 0.1-10mu m. The lotus seed paste has fresh, sweet and mellow taste, has the health care function oflowering blood pressure, blood lipid and blood sugar and is suitable to serve as an auxiliary health care product of the daily food of the patients with hypertension, hyperlipidemia, hyperglycemia and the like or vast consumers.

The invention discloses a fully-novel oral solid pharmaceutical composition. The pharmaceutical composition is an oral preparation prepared from hydrochlorothiazide, L-amlodipine, telmisartan and pharmaceutically acceptable auxiliary materials; and the oral preparation includes but is not limited to tablets or capsules. The composition is prepared from the following raw materials in parts by weight: 5-25 parts of hydrochlorothiazide, 2.5-5 parts of L-amlodipine, 20-80 parts of telmisartan, 0.1-0.5 part of sodium bicarbonate, 40-120 parts of microcrystalline cellulose, 20-60 parts of hydroxypropyl cellulose, 30-100 parts of lactose, 30-90 parts of compressible starch, 2-5 parts of low-substituted hydroxypropyl cellulose, 10-45 parts of crosslinked polyvinylpyrrolidone and 1-2 parts of magnesium stearate. The pharmaceutical composition disclosed by the invention has the advantages of reasonable and scientific prescription, low auxiliary material content and high bioavailability, and is a drug of first choice for treating hypertensive.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The invention discloses a compound traditional Chinese medicine for treating hypertension. The compound traditional Chinese medicine is prepared by the step of carrying out extraction separation on raw materials including uncaria rhynchophylla, ligusticum wallichii, angelica sinensis, rauvolfia verticillate and apocynum venetum with 0-75% ethanol and is prepared into a certain dosage form. The five drugs used together have the effects of calming liver wind and relieving dizziness, nourishing yin and invigorating pulse and are applied to patients suffering from yin deficiency and yang excess and venation stasis of hypertension symptoms. Pharmacodynamic studies show that the compound traditional Chinese medicine can obviously reduce the systolic pressure and the diastolic pressure of spontaneous hypertension and renal hypertension model animals and the antihypertensive effect is longlasting. Clinical research results show that the compound traditional Chinese medicine can effectively improve various traditional Chinese medicine symptoms of the patients suffering from yin deficiency and yang excess and venation stasis of hypertension and reduce the blood pressure of the patients without obvious adverse drug reaction. The compound traditional Chinese medicine can be prepared into a medically acceptable oral solid preparation such as a tablet, a capsule (a soft capsule or a hard capsule), granules and other dosage forms, is used for treating hypertension and is safe, effective and convenient to use.

The invention discloses a traditional Chinese medicine composition with the function of reducing blood pressure, as well as a preparation method thereof. The traditional Chinese medicine composition is prepared from perilla leaves, Apocynum venetum, rhizoma gastrodiae and uncaria according to a certain weight mixture ratio, and can be prepared to be any common orally taken medicament. The traditional Chinese medicine composition has the efficacy of reducing blood pressure and can be used for treating hypertension.

The invention belongs to the technical field of medicine and particularly relates to traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension. The traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension is prepared from, by weight, 11-19 parts of Chinese wolfberry fruits, 11-19 parts of eclipta, 11-19 parts of mulberries, 6-14 parts of black sesame, 11-19 parts of prepared rehmannia roots, 11-19 parts of astragalus membranaceus, 11-19 parts of rhizoma atractylodis macrocephalae, 11-19 parts of codonopsis pilosula, 11-19 parts of angelica sinensis, 11-19 parts of radix paeoniae alba, 11-19 parts of concha haliotidis, 6-14 parts of tribulus terrestris, 6-14 parts of apocynum venetum, 6-14 parts of gastrodia elata, 6-14 parts of uncaria, 5-13 parts of periostracum cicada, 5-13 parts of folium mori, 5-13 parts of chrysanthemums, 11-19 parts of tuber fleeceflower stems, 6-14 parts of cortex albiziae, 6-14 parts of wild jujube seeds, 4-8 parts of fructus evodiae and 4-8 parts of liquorice. The traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension can obviously reduce systolic pressure, diastolic pressure and mean arterial pressure of patients while western medicine reduces pressure basically, obviously avoid the clinical symptoms of patients like headache, dizziness, insomnia, tinnitus and annoyance and irritability, and improve the quality of life of patients.

The invention discloses a brand-new oral solid pharmaceutical composition. The pharmaceutical composition is an oral preparation prepared from hydrochlorothiazide, l-amlodipine, olmesartan medoxomil and pharmaceutically acceptable auxiliary materials, and the oral preparation comprises but is not limited to tablets or capsules. The composition comprises the following raw materials in parts by weight: 5-25 parts of hydrochlorothiazide, 2.5-5 parts of l-amlodipine, 20-40 parts of olmesartan medoxomil, 40-120 parts of microcrystalline cellulose, 30-90 parts of pregelatinized starch, 15-40 parts of low-substituted hydroxypropyl cellulose, 10-45 parts of crosslinked polyvinylpyrrolidone, 3-8 parts of silica and 1-2 parts of magnesium stearate. The pharmaceutical composition disclosed by the invention has the advantages of scientific and reasonable prescription, low auxiliary material content and high bioavailability, and is a drug of first choice for treating hypertension.

The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan medoxomil potassium, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L. The substantially pure crystalline forms of azilsartan medoxomil potassium of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan medoxomil potassium generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan medoxomil potassium, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.